SLPI and elafin: one glove, many fingers.

Elafin and SLPI (secretory leucocyte protease inhibitor) have multiple important roles both in normal homoeostasis and at sites of inflammation. These include antiprotease and antimicrobial activity as well as modulation of the response to LPS (lipopolysaccharide) stimulation. Elafin and SLPI are members of larger families of proteins secreted predominantly at mucosal sites, and have been shown to be modulated in multiple pathological conditions. We believe that elafin and SLPI are important molecules in the controlled functioning of the innate immune system, and may have further importance in the integration of this system with the adaptive immune response. Recent interest has focused on the influence of inflamed tissues on the recruitment and phenotypic modulation of cells of the adaptive immune system and, indeed, the local production of elafin and SLPI indicate that they are ideally placed in this regard. Functionally related proteins, such as the defensins and cathelicidins, have been shown to have direct effects upon dendritic cells with potential alteration of their phenotype towards type I or II immune responses. This review addresses the multiple functions of elafin and SLPI in the inflammatory response and discusses further their roles in the development of the adaptive immune response.

[1]  Y. Suzuki,et al.  Elastase inhibitor elafin is a new type of proteinase inhibitor which has a transglutaminase-mediated anchoring sequence termed "cementoin". , 1994, Journal of biochemistry.

[2]  B. Wieringa,et al.  SKALP/elafin: an elastase inhibitor from cultured human keratinocytes. Purification, cDNA sequence, and evidence for transglutaminase cross-linking. , 1993, The Journal of biological chemistry.

[3]  M. Ogawa,et al.  Immunohistochemical expression of SKALP/elafin in squamous cell carcinoma of human lung , 2002 .

[4]  L. Kwak,et al.  Toll-Like Receptor 4-Dependent Activation of Dendritic Cells by β-Defensin 2 , 2002, Science.

[5]  T. Ganz Defensins: antimicrobial peptides of innate immunity , 2003, Nature Reviews Immunology.

[6]  R. Pfundt,et al.  In situ demonstration of phosphorylated c‐jun and p38 MAP kinase in epidermal keratinocytes following ultraviolet B irradiation of human skin , 2001, The Journal of pathology.

[7]  Alistair R W Williams,et al.  Hormonal contraception can suppress natural antimicrobial gene transcription in human endometrium. , 2003, Fertility and sterility.

[8]  W. D. de Jong,et al.  Identification and Sequence Analysis of Two New Members of the SKALP/elafin and SPAI-2 Gene Family , 1997, The Journal of Biological Chemistry.

[9]  S. Wahl,et al.  Secretory Leukocyte Protease Inhibitor Suppresses the Inflammation and Joint Damage of Bacterial Cell Wall–Induced Arthritis , 1999, The Journal of experimental medicine.

[10]  C. Hack,et al.  Granzyme Activity in the Inflamed Lung Is Not Controlled by Endogenous Serine Proteinase Inhibitors1 , 2000, The Journal of Immunology.

[11]  Chris T. Amemiya,et al.  Somatic diversification of variable lymphocyte receptors in the agnathan sea lamprey , 2004, Nature.

[12]  E. Piitulainen,et al.  Increased plasma levels of serine proteinase inhibitors in lung cancer patients. , 2004, Anticancer research.

[13]  K. Knight,et al.  Secretory leukocyte proteinase inhibitor, alpha‐1‐antitrypsin deficiency and emphysema: Preliminary study, speculation and an hypothesis , 2003, Respirology.

[14]  F. Barone,et al.  Up-regulation of secretory leukocyte protease inhibitor (SLPI) in the brain after ischemic stroke: adenoviral expression of SLPI protects brain from ischemic injury. , 2003, Molecular pharmacology.

[15]  J. Schalkwijk,et al.  Extremely low levels of epidermal skin‐derived antileucoproteinase/elafin in a patient with impetigo herpetiformis , 1997, The British journal of dermatology.

[16]  K. Abromeit Music Received , 2023, Notes.

[17]  M. Rabinovitch,et al.  Targeted overexpression of elafin protects mice against cardiac dysfunction and mortality following viral myocarditis. , 1999, The Journal of clinical investigation.

[18]  C. Vogelmeier,et al.  Transforming growth factor‐β1 is a potent inhibitor of secretory leukoprotease inhibitor expression in a bronchial epithelial cell line , 2000 .

[19]  M. Sponer,et al.  Different susceptibility of elastase inhibitors to inactivation by proteinases from Staphylococcus aureus and Pseudomonas aeruginosa. , 1991, Biological chemistry Hoppe-Seyler.

[20]  G. Steffens,et al.  Antibacterial activity of antileukoprotease , 1996, Infection and immunity.

[21]  A. Kulkarni,et al.  Secretory leukocyte protease inhibitor mediates non-redundant functions necessary for normal wound healing , 2000, Nature Medicine.

[22]  P. Malfertheiner,et al.  Helicobacter pylori-Mediated Gastritis Induces Local Downregulation of Secretory Leukocyte Protease Inhibitor in the Antrum , 2004, Infection and Immunity.

[23]  D. Bainton,et al.  The Human Antibacterial Cathelicidin, hCAP-18, Is Synthesized in Myelocytes and Metamyelocytes and Localized to Specific Granules in Neutrophils , 1997 .

[24]  R. Pfundt,et al.  Constitutive and inducible expression of SKALP/elafin provides anti-elastase defense in human epithelia. , 1996, The Journal of clinical investigation.

[25]  S. Tajima,et al.  Elafin is induced in epidermis in skin disorders with dermal neutrophilic infiltration: interleukin‐1β and tumour necrosis factor‐α stimulate its secretion in vitro , 2000 .

[26]  Y. Bourbonnais,et al.  Anti-Inflammatory Effect of Pre-Elafin in Lipopolysaccharide-Induced Acute Lung Inflammation , 2002, Biological chemistry.

[27]  M. Koyama,et al.  Production of secretory leukocyte protease inhibitor by human amniotic membranes and regulation of its concentration in amniotic fluid. , 2001, Molecular human reproduction.

[28]  O. Levy Antimicrobial proteins and peptides: anti‐infective molecules of mammalian leukocytes , 2004, Journal of leukocyte biology.

[29]  D. Porteous,et al.  Adenoviral Augmentation of Elafin Protects the Lung Against Acute Injury Mediated by Activated Neutrophils and Bacterial Infection1 , 2001, The Journal of Immunology.

[30]  K. Yamanishi,et al.  Up-regulation of elafin/SKALP gene expression in psoriatic epidermis. , 1994, The Journal of investigative dermatology.

[31]  Hua Xie,et al.  Inhibition of histamine release from human mast cells by natural chymase inhibitors. , 2004, Acta pharmacologica Sinica.

[32]  J. Schalkwijk,et al.  The trappin gene family: proteins defined by an N-terminal transglutaminase substrate domain and a C-terminal four-disulphide core. , 1999, The Biochemical journal.

[33]  P. McCray,et al.  β-Defensins in Lung Host Defense , 2002 .

[34]  L. Matrisian,et al.  Regulation of intestinal alpha-defensin activation by the metalloproteinase matrilysin in innate host defense. , 1999, Science.

[35]  T. Curiel,et al.  Cross-Talk in the Innate Immune System: Neutrophils Instruct Recruitment and Activation of Dendritic Cells during Microbial Infection 1 , 2003, The Journal of Immunology.

[36]  C. Haslett,et al.  Elafin (elastase‐specific inhibitor) has anti‐microbial activity against Gram‐positive and Gram‐negative respiratory pathogens , 1999, FEBS letters.

[37]  B. Richardson,et al.  Salivary secretory leukocyte protease inhibitor is associated with reduced transmission of human immunodeficiency virus type 1 through breast milk. , 2002, The Journal of infectious diseases.

[38]  A. Janoff,et al.  Proteases and lung injury. A state-of-the-art minireview. , 1983, Chest.

[39]  T. Betsuyaku,et al.  Role of secretory leukocyte protease inhibitor in the development of subclinical emphysema , 2002, European Respiratory Journal.

[40]  G. Tremblay,et al.  Human Alveolar Macrophages Express Elafin and Secretory Leukocyte Protease Inhibitor , 2001, Zeitschrift fur Naturforschung. C, Journal of biosciences.

[41]  J. Sallenave,et al.  Secretory leukocyte proteinase inhibitor is a major leukocyte elastase inhibitor in human neutrophils , 1997, Journal of leukocyte biology.

[42]  P. Sime,et al.  Overexpression of Granulocyte-Macrophage , 2007 .

[43]  S. Wahl,et al.  Secretory Leukocyte Protease Inhibitor Binds to Annexin II, a Cofactor for Macrophage HIV-1 Infection , 2004, The Journal of experimental medicine.

[44]  K. Rabe,et al.  Regulation of secretory leukocyte proteinase inhibitor (SLPI) production by human bronchial epithelial cells: increase of cell-associated SLPI by neutrophil elastase. , 2000, Journal of investigative medicine : the official publication of the American Federation for Clinical Research.

[45]  J. Sallenave,et al.  Characterization of the ovine ortholog of secretory leukoprotease inhibitor , 2005, Mammalian Genome.

[46]  A. Schollenberger,et al.  Pathogenesis of mousepox in H-2(d) mice: evidence for MHC class I-restricted CD8(+) and MHC class II-restricted CD4(+) CTL antiviral activity in the lymph nodes, spleen and skin, but not in the conjunctivae. , 2001, Microbes and infection.

[47]  J. Sallenave,et al.  Purification and characterization of elastase-specific inhibitor. Sequence homology with mucus proteinase inhibitor. , 1991, Biological chemistry Hoppe-Seyler.

[48]  Domenico Romeo,et al.  Cathelicidins: a novel protein family with a common proregion and a variable C‐terminal antimicrobial domain , 1995, FEBS letters.

[49]  Ji Ming Wang,et al.  Ll-37, the Neutrophil Granule–And Epithelial Cell–Derived Cathelicidin, Utilizes Formyl Peptide Receptor–Like 1 (Fprl1) as a Receptor to Chemoattract Human Peripheral Blood Neutrophils, Monocytes, and T Cells , 2000, The Journal of experimental medicine.

[50]  M. Jordana,et al.  Regulation of secretory leukocyte proteinase inhibitor (SLPI) and elastase-specific inhibitor (ESI/elafin) in human airway epithelial cells by cytokines and neutrophilic enzymes. , 1994, American journal of respiratory cell and molecular biology.

[51]  V. Pascual,et al.  Dendritic cells control B cell growth and differentiation. , 2005, Current directions in autoimmunity.

[52]  M. Si-Tahar,et al.  Constitutive and regulated secretion of secretory leukocyte proteinase inhibitor by human intestinal epithelial cells. , 2000, Gastroenterology.

[53]  C. Haslett Granulocyte apoptosis and its role in the resolution and control of lung inflammation. , 1999, American journal of respiratory and critical care medicine.

[54]  S. Wahl,et al.  Secretory leukocyte protease inhibitor suppresses the production of monocyte prostaglandin H synthase-2, prostaglandin E2, and matrix metalloproteinases. , 1997, The Journal of clinical investigation.

[55]  G. Slade,et al.  Salivary Secretory Leukocyte Protease Inhibitor and Oral Candidiasis in Human Immunodeficiency Virus Type 1-Infected Persons , 2004, Infection and Immunity.

[56]  A. Klingelhutz,et al.  Microarray analysis identifies differentiation-associated genes regulated by human papillomavirus type 16 E6. , 2003, Virology.

[57]  D. Bainton,et al.  The human antibacterial cathelicidin, hCAP-18, is synthesized in myelocytes and metamyelocytes and localized to specific granules in neutrophils. , 1997, Blood.

[58]  P. Matzinger Tolerance, danger, and the extended family. , 1994, Annual review of immunology.

[59]  H. Erdjument-Bromage,et al.  Conversion of Proepithelin to Epithelins Roles of SLPI and Elastase in Host Defense and Wound Repair , 2002, Cell.

[60]  Y. Bourbonnais,et al.  Inhibition of human neutrophil elastase-induced acute lung injury in hamsters by recombinant human pre-elafin (trappin-2). , 2002, Chest.

[61]  M. Ponec,et al.  SKALP/elafin is an inducible proteinase inhibitor in human epidermal keratinocytes. , 1994, Journal of cell science.

[62]  G. Wilson,et al.  Elafin, a serine elastase inhibitor, attenuates post-cardiac transplant coronary arteriopathy and reduces myocardial necrosis in rabbits afer heterotopic cardiac transplantation. , 1996, The Journal of clinical investigation.

[63]  L. Kuhn,et al.  Secretory leukocyte protease inhibitor in vaginal fluids and perinatal human immunodeficiency virus type 1 transmission. , 2001, The Journal of infectious diseases.

[64]  Ji Ming Wang,et al.  β-Defensins: Linking Innate and Adaptive Immunity Through Dendritic and T Cell CCR6 , 1999 .

[65]  A. Lentsch,et al.  Inhibition of NF-κB Activation and Augmentation of IκBβ by Secretory Leukocyte Protease Inhibitor during Lung Inflammation , 1999 .

[66]  R. Simmen,et al.  Complementary DNA cloning and regulation of expression of the messenger RNA encoding a pregnancy-associated porcine uterine protein related to human antileukoproteinase. , 1990, Molecular endocrinology.

[67]  M. Kashiwagi,et al.  Localization of porcine trappin-2 (SKALP/elafin) in trachea and large intestine by in situ hybridization and immunohistochemistry , 2000, Histochemistry and Cell Biology.

[68]  K. Shirato,et al.  Secretion and gene expression of secretory leukocyte protease inhibitor by human airway submucosal glands. , 2001, American journal of physiology. Lung cellular and molecular physiology.

[69]  Z. Xing,et al.  Enhanced immunogenicity of BCG vaccine by using a viral-based GM-CSF transgene adjuvant formulation. , 2002, Vaccine.

[70]  J. Sallenave,et al.  Characterization and gene sequence of the precursor of elafin, an elastase-specific inhibitor in bronchial secretions. , 1993, American journal of respiratory cell and molecular biology.

[71]  D. Webb,et al.  Adenoviral Gene Delivery of Elafin and Secretory Leukocyte Protease Inhibitor Attenuates NF-κB-Dependent Inflammatory Responses of Human Endothelial Cells and Macrophages to Atherogenic Stimuli1 , 2004, The Journal of Immunology.

[72]  P. Nibbering,et al.  Expression of β‐defensin 1 and 2 mRNA by human monocytes, macrophages and dendritic cells , 2002 .

[73]  D. Ganea,et al.  A Novel Signaling Pathway Mediates the Inhibition of CCL3/4 Expression by Prostaglandin E2* , 2004, Journal of Biological Chemistry.

[74]  Y. Kaneda,et al.  Gene Transfer of the Serine Elastase Inhibitor Elafin Protects Against Vein Graft Degeneration , 2000, Circulation.

[75]  Y. Suzuki,et al.  Cryptic Origin of SPAI, a Plasma Protein with a Transglutaminase Substrate Domain and the WAP Motif, Revealed by in Situ Hybridization and Immunohistochemistry* , 1996, The Journal of Biological Chemistry.

[76]  J. Orenstein,et al.  Secretory leukocyte protease inhibitor (SLPI) in mucosal fluids inhibits HIV‐1 , 1997 .

[77]  V. Bafna,et al.  Human beta-defensin 2 is a salt-sensitive peptide antibiotic expressed in human lung. , 1998, The Journal of clinical investigation.

[78]  P. Lachmann,et al.  Streptococcal Inhibitor of Complement Inhibits Two Additional Components of the Mucosal Innate Immune System: Secretory Leukocyte Proteinase Inhibitor and Lysozyme , 2002, Infection and Immunity.

[79]  Dorthea A. Johnson,et al.  Salivary secretory leukocyte protease inhibitor increases in HIV infection. , 2004, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.

[80]  C. Haslett,et al.  Regulation of Pulmonary and Systemic Bacterial Lipopolysaccharide Responses in Transgenic Mice Expressing Human Elafin , 2003, Infection and Immunity.

[81]  L. Kwak,et al.  Mediators of Innate Immunity That Target Immature, But Not Mature, Dendritic Cells Induce Antitumor Immunity When Genetically Fused with Nonimmunogenic Tumor Antigens , 2001, The Journal of Immunology.

[82]  S. Knight,et al.  Dendritic cells, antigen distribution and the initiation of primary immune responses to self and non-self antigens. , 2002, Seminars in cancer biology.

[83]  R. Crystal,et al.  Modulation of secretory leukoprotease inhibitor gene expression in human bronchial epithelial cells by phorbol ester. , 1994, The Journal of clinical investigation.

[84]  R. Brunham,et al.  GM-CSF Transgene-Based Adjuvant Allows the Establishment of Protective Mucosal Immunity Following Vaccination with Inactivated Chlamydia trachomatis1 , 2002, The Journal of Immunology.

[85]  G. Ashcroft,et al.  Aberrant mucosal wound repair in the absence of secretory leukocyte protease inhibitor , 2004, Thrombosis and Haemostasis.

[86]  T. Nonaka,et al.  Administration of truncated secretory leukoprotease inhibitor ameliorates bleomycin-induced pulmonary fibrosis in hamsters. , 1996, American journal of respiratory and critical care medicine.

[87]  F. Dallegri,et al.  Tissue injury in neutrophilic inflammation , 1997, Inflammation Research.

[88]  J. Schröder,et al.  Human leukocyte elastase and cathepsin G are specific inhibitors of C5a‐dependent neutrophil enzyme release and chemotaxis , 2004, Experimental dermatology.

[89]  J. Sallenave,et al.  Gene delivery of the elastase inhibitor elafin protects macrophages from neutrophil elastase‐mediated impairment of apoptotic cell recognition , 2004, FEBS letters.

[90]  J. Lafitte,et al.  Expression of human mucous proteinase inhibitor in respiratory tract: a study by in situ hybridization. , 1995, Journal of Histochemistry and Cytochemistry.

[91]  S. Kumkate,et al.  IL-10 regulates early IL-12-mediated immune responses induced by the radiation-attenuated schistosome vaccine. , 2003, International immunology.

[92]  J. Sallenave,et al.  Differential regulation of secretory leukocyte protease inhibitor and elafin by progesterone. , 2003, Biochemical and biophysical research communications.

[93]  A. Szarka,et al.  Human SLPI inactivation after cigarette smoke exposure in a new in vivo model of pulmonary oxidative stress. , 2001, American journal of physiology. Lung cellular and molecular physiology.

[94]  Robert Bals,et al.  Antimicrobial Peptides , 2012, Drugs.

[95]  Fenyu Jin,et al.  Secretory Leukocyte Protease Inhibitor Interferes with Uptake of Lipopolysaccharide by Macrophages , 1999, Infection and Immunity.

[96]  H. Shiota,et al.  The effect of topically applied secretory leukocyte protease inhibitor on the eosinophil response in the late phase of allergic conjunctivitis , 2003, Current eye research.

[97]  E. Christophers,et al.  Antileukoprotease in human skin: an antibiotic peptide constitutively produced by keratinocytes. , 1998, Biochemical and biophysical research communications.

[98]  J. Sallenave,et al.  Secretion of mucus proteinase inhibitor and elafin by Clara cell and type II pneumocyte cell lines. , 1993, American journal of respiratory cell and molecular biology.

[99]  C. Sano,et al.  Effects of secretory leukocyte protease inhibitor on the tumor necrosis factor-alpha production and NF-kappaB activation of lipopolysaccharide-stimulated macrophages. , 2003, Cytokine.

[100]  Y. Tsao,et al.  Co‐vaccination with adeno‐associated virus vectors encoding human papillomavirus 16 L1 proteins and adenovirus encoding murine GM‐CSF can elicit strong and prolonged neutralizing antibody , 2005, International journal of cancer.

[101]  J. Stolk,et al.  Inhibition of lipopolysaccharide-induced pulmonary emphysema by intratracheally instilled recombinant secretory leukocyte proteinase inhibitor. , 1993, The American review of respiratory disease.

[102]  J. Schalkwijk,et al.  Immunohistochemical localization of SKALP/elafin in psoriatic epidermis. , 1993, The Journal of investigative dermatology.

[103]  H. Critchley,et al.  Regulation of natural antibiotic expression by inflammatory mediators and mimics of infection in human endometrial epithelial cells. , 2002, Molecular human reproduction.

[104]  S. Wahl,et al.  Inhibition of human immunodeficiency virus type 1 infectivity by secretory leukocyte protease inhibitor occurs prior to viral reverse transcription. , 1997, Blood.

[105]  J. Sallenave,et al.  Elafin in human endometrium: an antiprotease and antimicrobial molecule expressed during menstruation. , 2003, The Journal of clinical endocrinology and metabolism.

[106]  T. Nakamura,et al.  Secretory Leukoprotease Inhibitor Augments Hepatocyte Growth Factor Production in Human Lung Fibroblasts , 1991 .

[107]  D. Ganea,et al.  Prostaglandin E2 Promotes the Survival of Bone Marrow-Derived Dendritic Cells1 , 2004, The Journal of Immunology.

[108]  P. Hiemstra,et al.  Antileukoprotease; An endogenous protein in the innate mucosal defense against fungi , 1997 .

[109]  D. Radzioch,et al.  Secretory Leukocyte Protease Inhibitor: A Macrophage Product Induced by and Antagonistic to Bacterial Lipopolysaccharide , 1997, Cell.

[110]  R. Levine,et al.  Cathepsin B, L, and S Cleave and Inactivate Secretory Leucoprotease Inhibitor* , 2001, The Journal of Biological Chemistry.

[111]  J. Sallenave,et al.  Antimicrobial Activity of Murine Lung Cells against Staphylococcus aureus Is Increased In Vitro and In Vivo after Elafin Gene Transfer , 2005, Infection and Immunity.

[112]  J. Schalkwijk,et al.  Skin-derived antileukoproteinase (SKALP), an elastase inhibitor from human keratinocytes. Purification and biochemical properties. , 1991, Biochimica et biophysica acta.

[113]  L. Alexander,et al.  Evolution of the trappin multigene family in the Suidae. , 1998, Journal of biochemistry.

[114]  M. Rabinovitch,et al.  Suppressed smooth muscle proliferation and inflammatory cell invasion after arterial injury in elafin-overexpressing mice. , 2000, The Journal of clinical investigation.

[115]  A. Lentsch,et al.  Anti-inflammatory effects of mutant forms of secretory leukocyte protease inhibitor. , 2000, The American journal of pathology.

[116]  Peter P. Liu,et al.  Elafin-overexpressing mice have improved cardiac function after myocardial infarction. , 2004, American journal of physiology. Heart and circulatory physiology.

[117]  A. Vitiello,et al.  Cutting Edge: Mast Cell Antimicrobial Activity Is Mediated by Expression of Cathelicidin Antimicrobial Peptide 1 , 2003, The Journal of Immunology.

[118]  T. Kohno,et al.  The cloning and characterization of a murine secretory leukocyte protease inhibitor cDNA. , 1997, Biochemical and biophysical research communications.

[119]  J. Gauldie,et al.  Elafin/elastase-specific inhibitor in bronchoalveolar lavage of normal subjects and farmer's lung. , 1996, American journal of respiratory and critical care medicine.

[120]  T. Saheki,et al.  Primary structure of the human elafin precursor preproelafin deduced from the nucleotide sequence of its gene and the presence of unique repetitive sequences in the prosegment. , 1992, Biochemical and biophysical research communications.

[121]  T. Ganz,et al.  Wound Healing and Expression of Antimicrobial Peptides/Polypeptides in Human Keratinocytes, a Consequence of Common Growth Factors1 , 2003, The Journal of Immunology.

[122]  J. Schalkwijk,et al.  Regulation of SLPI and elafin release from bronchial epithelial cells by neutrophil defensins. , 2000, American journal of physiology. Lung cellular and molecular physiology.

[123]  D. Shugars Endogenous mucosal antiviral factors of the oral cavity. , 1999, The Journal of infectious diseases.

[124]  M. Krohn,et al.  Levels of vaginal secretory leukocyte protease inhibitor are decreased in women with lower reproductive tract infections. , 2000, American journal of obstetrics and gynecology.

[125]  K. Ohlsson,et al.  The presence of elafin, SLPI, IL1-RA and STNFalpha RI in head and neck squamous cell carcinomas and their relation to the degree of tumour differentiation. , 2002, Mediators of inflammation.

[126]  B. Pulendran Modulating vaccine responses with dendritic cells and Toll‐like receptors , 2004, Immunological reviews.

[127]  J. Schalkwijk,et al.  Expression of SKALP/elafin during wound healing in human skin , 1996, Archives of Dermatological Research.

[128]  A. Ding,et al.  Murine Macrophages Produce Secretory Leukocyte Protease Inhibitor During Clearance of Apoptotic Cells: Implications for Resolution of the Inflammatory Response 1 , 2003, The Journal of Immunology.

[129]  K. Furusho,et al.  Prostaglandin E2 at priming of naive CD4+ T cells inhibits acquisition of ability to produce IFN-gamma and IL-2, but not IL-4 and IL-5. , 1995, Journal of immunology.

[130]  P. Ye,et al.  The protective effect of a Schistosoma japonicum Chinese strain 23 kDa plasmid DNA vaccine in pigs is enhanced with IL-12. , 2004, Vaccine.

[131]  C. Haslett,et al.  Human neutrophil elastase regulates the expression and secretion of elafin (elastase‐specific inhibitor) in type II alveolar epithelial cells , 1999, FEBS letters.

[132]  J. Sallenave,et al.  Trappin ovine molecule (TOM), the ovine ortholog of elafin, is an acute phase reactant in the lung. , 2004, Physiological genomics.

[133]  G. Lippens,et al.  Solution structure of R-elafin, a specific inhibitor of elastase. , 1997, Journal of molecular biology.

[134]  D. Radzioch,et al.  Lipopolysaccharide-Related Stimuli Induce Expression of the Secretory Leukocyte Protease Inhibitor, a Macrophage-Derived Lipopolysaccharide Inhibitor , 1998, Infection and Immunity.

[135]  P. Matzinger The Danger Model: A Renewed Sense of Self , 2002, Science.

[136]  L. Hydo,et al.  Secretory leukocyte protease inhibitor, an inhibitor of neutrophil activation, is elevated in serum in human sepsis and experimental endotoxemia , 2000, Critical care medicine.

[137]  T. Shimizu,et al.  Effects of secretory leucocyte protease inhibitor on the production of the anti‐inflammatory cytokines, IL‐10 and transforming growth factor‐beta (TGF‐β), by lipopolysaccharide‐stimulated macrophages , 2000, Clinical and experimental immunology.

[138]  M. Brenner,et al.  IL-6 Production by Pulmonary Dendritic Cells Impedes Th1 Immune Responses 1 , 2003, The Journal of Immunology.

[139]  H. Jörnvall,et al.  The human antimicrobial and chemotactic peptides LL-37 and alpha-defensins are expressed by specific lymphocyte and monocyte populations. , 2000, Blood.

[140]  M. Furukawa,et al.  Accelerated Evolution in Inhibitor Domains of Porcine Elafin Family Members (*) , 1996, The Journal of Biological Chemistry.

[141]  Z. Stelmasiak,et al.  Increased Serum Levels of Endogenous Protectant Secretory Leukocyte Protease Inhibitor in Acute Ischemic Stroke Patients , 2002, Cerebrovascular Diseases.

[142]  Daying Zhang,et al.  Secretory Leukocyte Protease Inhibitor Mediates Proliferation of Human Endometrial Epithelial Cells by Positive and Negative Regulation of Growth-associated Genes* , 2002, The Journal of Biological Chemistry.

[143]  P. Ward,et al.  Regulatory effects of endogenous protease inhibitors in acute lung inflammatory injury. , 1999, Journal of immunology.

[144]  P. C. White,et al.  Supernatants of Pseudomonas aeruginosa induce the Pseudomonas‐specific antibiotic elafin in human keratinocytes , 2003, Experimental dermatology.

[145]  J. Meis,et al.  Induction of SLPI (ALP/HUSI-I) in epidermal keratinocytes. , 1998, The Journal of investigative dermatology.

[146]  Robert E. W. Hancock,et al.  The Cationic Antimicrobial Peptide LL-37 Modulates Dendritic Cell Differentiation and Dendritic Cell-Induced T Cell Polarization1 , 2004, The Journal of Immunology.

[147]  N. McElvaney,et al.  Secretory Leucoprotease Inhibitor Prevents Lipopolysaccharide-induced IκBα Degradation without Affecting Phosphorylation or Ubiquitination* , 2002, The Journal of Biological Chemistry.

[148]  H. Wigzell,et al.  The Expression of the Gene Coding for the Antibacterial Peptide LL-37 Is Induced in Human Keratinocytes during Inflammatory Disorders* , 1997, The Journal of Biological Chemistry.

[149]  T. Muramatsu,et al.  Secretory leukocyte protease inhibitor is a novel inhibitor of fibroblast-mediated collagen gel contraction. , 2000, Experimental cell research.

[150]  J. Sallenave The role of secretory leukocyte proteinase inhibitor and elafin (elastase-specific inhibitor/skin-derived antileukoprotease) as alarm antiproteinases in inflammatory lung disease , 2000, Respiratory research.

[151]  J. Sallenave,et al.  Isolation of elafin and elastase-specific inhibitor (ESI) from bronchial secretions. Evidence of sequence homology and immunological cross-reactivity. , 1992, Biological chemistry Hoppe-Seyler.

[152]  R. Stockley,et al.  Relationship between airway inflammation and the frequency of exacerbations in patients with smoking related COPD , 2001, Thorax.

[153]  L. Bingle,et al.  Cytokine-mediated induction of the human elafin gene in pulmonary epithelial cells is regulated by nuclear factor-kappaB. , 2001, American journal of respiratory cell and molecular biology.

[154]  B. Rasche,et al.  An elastase-specific inhibitor from human bronchial mucus. Isolation and characterization. , 1981, Hoppe-Seyler's Zeitschrift fur physiologische Chemie.

[155]  Yuetsu Tanaka,et al.  Microbial Compounds Selectively Induce Th1 Cell-Promoting or Th2 Cell-Promoting Dendritic Cells In Vitro with Diverse Th Cell-Polarizing Signals1 , 2002, The Journal of Immunology.

[156]  P. Sime,et al.  Overexpression of granulocyte-macrophage colony-stimulating factor induces pulmonary granulation tissue formation and fibrosis by induction of transforming growth factor-beta 1 and myofibroblast accumulation. , 1997, The American journal of pathology.

[157]  Kutty Selva Nandakumar,et al.  Antileukoproteinase: modulation of neutrophil function and therapeutic effects on anti-type II collagen antibody-induced arthritis. , 2004, Arthritis and rheumatism.

[158]  J. Calafat,et al.  Human cathelicidin, hCAP-18, is processed to the antimicrobial peptide LL-37 by extracellular cleavage with proteinase 3. , 2001, Blood.

[159]  D. Dripps,et al.  Secretory leukocyte protease inhibitor: a human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitro. , 1995, The Journal of clinical investigation.

[160]  R. Huber,et al.  The 2.5 A X‐ray crystal structure of the acid‐stable proteinase inhibitor from human mucous secretions analysed in its complex with bovine alpha‐chymotrypsin. , 1988, The EMBO journal.

[161]  C. Nathan,et al.  Suppression of macrophage responses to bacterial lipopolysaccharide by a non-secretory form of secretory leukocyte protease inhibitor. , 1999, Biochimica et biophysica acta.

[162]  D. Porteous,et al.  Regulation of adenovirus-mediated elafin transgene expression by bacterial lipopolysaccharide. , 2001, Human gene therapy.

[163]  J. Fransen,et al.  Antileukoprotease is associated with elastin fibers in the extracellular matrix of the human lung. An immunoelectron microscopic study. , 1989, The American review of respiratory disease.

[164]  J. Chi,et al.  Elafin expression in human fetal and adult submandibular glands , 2002, Histochemistry and Cell Biology.

[165]  C. Colaco Towards a unified theory of immunity: dendritic cells, stress proteins and antigen capture. , 1998, Cellular and molecular biology.

[166]  J. Schalkwijk,et al.  Skin-derived antileukoproteinase (SKALP) is decreased in pustular forms of psoriasis. A clue to the pathogenesis of pustule formation? , 1996, Archives of Dermatological Research.

[167]  T. O'brien,et al.  Antimicrobial Peptides: Mediators of Innate Immunity as Templates for the Development of Novel Anti-Infective and Immune Therapeutics , 2008 .

[168]  K. Ohlsson,et al.  Identification of SLPI (Secretory Leukocyte Protease Inhibitor) in Human Mast Cells Using Immunohistochemistry and In Situ Hybridisation , 1999, Biological chemistry.

[169]  K. Rabe,et al.  Role of defensins in inflammatory lung disease , 2002, Annals of medicine.

[170]  A. Chinnaiyan,et al.  In vivo suppression of immune complex-induced alveolitis by secretory leukoproteinase inhibitor and tissue inhibitor of metalloproteinases 2. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[171]  E. Klasen,et al.  Characterization of a low molecular weight anti-elastase isolated from human bronchial secretion. , 1985, Experimental lung research.

[172]  C. Boudier,et al.  The proteinase: mucus proteinase inhibitor binding stoichiometry. , 1992, The Journal of biological chemistry.

[173]  R. Pfundt,et al.  TNF-α and serum induce SKALP/elafin gene expression in human keratinocytes by a p38 MAP kinase-dependent pathway , 2000, Archives of Dermatological Research.

[174]  J. Schröder,et al.  Elafin: an elastase-specific inhibitor of human skin. Purification, characterization, and complete amino acid sequence. , 1990, The Journal of biological chemistry.

[175]  J. Sallenave,et al.  The antimicrobial antiproteinase elafin binds to lipopolysaccharide and modulates macrophage responses. , 2005, American journal of respiratory cell and molecular biology.